A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

a study on High Blood Pressure Pulmonary Hypertension Pulmonary Arterial Hypertension

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around

Description

Summary

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart.

This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Official Title

A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION

Keywords

Pulmonary Hypertension, Open Label

Eligibility

For people ages 18 years and up

This study is seeking participants who are:

  • aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study.
  • willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • do not have worsening or hospitalization for worsening PAH during the qualifying study.
  • not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH.
  • do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study.
  • not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem).
  • not currently prescribed or taking medicines called as GLP-1 agonist.

Locations

  • UCSF Health St. Mary's Hospital accepting new patients
    San Francisco California 94117 United States
  • Heart and Vascular Center accepting new patients
    San Francisco California 94143 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
ID
NCT07073820
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 36 study participants
Last Updated
Contact us about this trial